



The Nifty previous session ended 0.06% down at 17203.95. It opened on a flat note and remained range-bound throughout the session towards ending with another Doji candle. Critical resistance placed around 17300 remained unharmed. Post recovery Doji candles might be a sign of upcoming weakness. Hence, staying cautious on rise is advised. Trading range is likely to be 17000-17300. However, on the flip side, successful closing above 17300 may push the Benchmark Index further higher towards 17500.

On the Nifty hourly chart, direction of the leading indicators suggesting upside is limited till 17300 as of now. Short-term trading range is likely to be 17000-17300.

Nifty patterns on multiple periods suggest; the benchmark index ended on an indecisive note. Critical resistance placed around 17300 yet to be taken out for further rise, however that looks unlikely. Chart pattern suggesting range-bound oscillation with a negative bias.

Nifty Crucial Supports & Resistances-

Supports- 17100, 17000 Resistances- 17300, 17500

Open Positional Calls-

T+10 POSITIONAL SELL-
| Futures Segment | GRASIM Fut @ 1610-1620, TGT- 1520, Closing SL- closing above 1670

T+5 Positional Sell-
| Futures Segment | SAIL Fut @ 111-112, TGT- 102, Closing SL- closing above 117

T+10 POSITIONAL SELL
| Futures Segment | SBIN Fut @ 460-465, TGT- 435, SL- closing above 480

T+2 BUY
| Cash Segment | TCS @ 3690-3680, TGT- 3760, SL- closing below 3640

T+10 INST POSITIONAL SELL
| Futures Segment | ICICI BANK Jan Fut @ 740-745, TGT- 705, SL- closing above 765

T+14 INST POSITIONAL SELL
| Futures Segment | UPL Jan Fut @ 770-775, TGT- 705, SL- closing above 810

T+3 BUY
| Cash Segment | CADILA @ 477-475, TGT- 495, SL- closing below 465

T+10 INST POSITIONAL BUY
| Cash Segment | IPCA LAB @ 2160-2150, TGT- 2270, SL- closing below 2090

T+2 BUY
| Cash Segment | IPCA LAB @ 2160-2150, TGT- 2210, SL- closing below 2120

T+7 INST POSITIONAL SELL
| Futures Segment | RIL Fut @ 2370-2380, TGT- 2280, SL- closing above 2430

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks closed the penultimate trading session little changed, as gains in information technology stocks were offset by losses in energy, oil & gas and metal stocks, with index heavyweight Reliance Industries Ltd. shedding little less than 2%. Trading volumes were thin in a rangebound session on monthly F&O expiry day.

Nifty index ended 0.06% lower at 17,204. The broader markets represented by the NIFTY 500 Index ended 0.14% lower, ending at 14,842. Among the sectorial indices NIFTY IT was the top gainer, gaining by 1%, followed by NIFTY Pharma was gaining by 0.44%. NIFTY Metal was the top loser losing by 1.17%.

NTPC was the top gainer, gaining by 3.05%, followed by HCL Tech and Cipla gained by 1.95% & 1.84% respectively. Bajaj Auto was the top loser, losing by 1.89%, followed by RIL and UPL which fell by 1.81% & 1.54% respectively.

The Advance : Decline ratio stood at 967:1144

Market Turnover (In Crore) 30-12-2021

Name	Last	Previous
NSE Cash	*NA	43474.89
NSE F&O	12317453.31	5282517.94
BSE Cash	3,907.96	4,057.36
BSE F&O	*NA	132.30

FII Derivatives Flow (In Crore) 29-12-2021*

Instrument	Purchase	Sale	Net
Index Future	5570.47	5732.12	-161.65
Index Option	478975.67	474342.27	4633.4
Stock Future	27846.91	28111.36	-264.45
Stock Option	14513.98	14330.54	183.44

Institutional Flow (In Crore) 30-12-2021

Institution	Purchase	Sale	Net
FII	4512.12	5498.44	986.32
DII	9450.33	8872.59	577.74

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	3.05	1.89	32394253	7783183
HCL Technologies	1.95	7.30	4518139	5568069
Cipla	1.84	4.73	1729705	2454915
Indusind Bank	1.77	1.64	12354342	5831596
Dr. Reddy'S	1.48	4.47	553146	386306

NIFTY Top Losers


Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Tata Steel	1.37	2.36	4114093	3709652
JSW Steel	1.54	0.68	3713255	2806376
UPL	1.54	1.07	1686223	1456017
RIL	1.81	0.26	13537254	3948228
Bajaj Auto	1.89	0.84	594987	244064

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 6:45PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	57794.32	12.17	0.02	0.84	1.28	2.25	21.04
Nifty	17203.95	9.65	0.06	0.77	1.30	2.35	23.04
BSE M Cap	24630.81	54.05	0.22	0.04	0.23	2.46	37.57
BSE S Cap	29121.04	55.01	0.19	2.04	4.24	3.70	61.48
Nifty MC 100	30023.25	112.05	0.37	0.32	1.26	1.19	44.75
BSE Auto	24394.74	145.72	0.59	0.37	1.69	2.22	17.54
BSE Capgoods	28566.17	58.89	0.21	0.86	6.22	10.01	52.64
BSE FMCG	13611.44	11.46	0.08	0.43	0.57	8.42	7.38
BSE Metal	18849.42	219.55	1.15	2.25	3.47	6.60	63.35
BSE Oil&Gas	17306.55	250.54	1.43	1.62	1.12	5.44	22.63
BSE Healthcare	25993.10	132.92	0.51	3.51	1.93	0.38	20.45
BSE Power	3469.27	26.05	0.75	2.41	0.37	8.46	68.27
BSE Realty	3792.97	38.02	0.99	1.25	0.18	7.57	54.86
BSE ConsDur	43896.68	188.66	0.43	1.72	1.85	6.19	45.95
BSE Bank	39866.49	13.08	0.03	0.31	2.24	6.70	10.90
BSE IT	37812.32	361.27	0.96	3.07	9.98	9.86	55.81

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.52	0.03	1.66	2.08	5.50	2.45	65.07
UK	0.99	0.03	2.76	6.83	21.76	3.62	362.44
Brazil	4.55	0.01	0.13	1.86	6.67	6.54	39.45
Japan	0.07	0.01	12.70	7.58	24.56	1.39	238.10
Australia	1.63	0.10	6.40	2.39	3.61	9.33	66.22
India	6.47	0.01	0.12	0.08	2.26	3.97	10.22
Switzerland	0.15	0.01	6.48	17.78	36.48	9.76	73.04
Germany	0.19	0.01	5.44	22.09	44.41	2.51	65.91

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.42	0.32	0.43	1.11	1.01	0.24	1.50
USD Index	96.14	0.21	0.22	0.07	0.16	2.03	7.21
YUAN	6.37	0.01	0.11	0.07	0.16	1.10	2.33
GBP	1.35	0.00	0.10	0.51	1.34	0.02	1.09
EUR	1.13	0.00	0.31	0.11	0.21	2.30	8.00
YEN	115.14	0.19	0.17	0.65	1.71	3.34	10.38

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2217.00	2.00	0.09	6.81	19.88	53.00	62.30
Baltic Dirty	786.00	2.00	0.25	1.87	9.02	25.56	68.67
SG Dubai HY	6.29	0.20	3.08	2.61	63.38	231.05	535.35

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	36488.63	90.42	0.25	2.81	5.81	7.81	19.99
Nasdaq	15766.21	15.50	0.10	2.77	1.47	9.12	22.50
S&P 500	4793.06	6.71	0.14	3.09	4.95	11.27	28.43
FTSE100	7416.22	6.53	0.09	1.60	5.02	4.62	13.09
CAC40	7171.60	10.98	0.15	0.93	6.72	10.01	28.09
DAX	15839.65	11.89	0.08	1.58	4.90	3.80	15.46
Mexico IPC	52748.93	489.55	0.92	0.66	6.14	2.65	18.02
Brazil Bovespa	104107.2	757.00	0.72	1.32	2.15	6.19	12.53
Russian RTS	1588.70	1.11	0.07	0.05	3.47	10.64	14.50
Japan Nikkei	28791.71	115.17	0.40	0.02	3.49	2.24	4.91
Hang Seng	23112.01	25.47	0.11	0.04	1.55	5.96	14.86
Taiwan Index	18218.84	29.44	0.16	1.52	4.54	7.58	24.04
Shanghai Comp	3619.19	22.19	0.62	0.66	1.55	1.43	6.00
KOSPI	2977.65	15.64	0.52	0.68	4.88	2.97	3.63
Malaysia KLCI	1543.61	1.43	0.09	1.79	1.96	0.38	6.13
Jakarta Comp	6581.48	19.20	0.29	0.40	0.73	4.68	10.08
Philippine SE	7334.56	48.06	0.66	3.03	1.86	5.49	2.73
Thai Exch	1657.62	4.29	0.26	0.98	5.67	3.23	14.37

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	75.93	0.58	0.76	4.43	14.81	1.27	56.98
BRENT Crude	78.77	0.49	0.62	2.46	13.74	2.58	55.89
Natural Gas	3.93	0.08	2.00	1.74	12.85	34.01	36.40

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1801.13	3.68	0.20	0.43	1.49	2.51	4.93
Silver(\$/Ounce)	22.73	0.11	0.48	0.69	0.49	2.50	14.78
Aluminium	2809.25	31.25	1.10	6.09	6.43	2.95	41.42
Copper	9725.50	130.50	1.36	2.77	0.65	6.01	23.97
Zinc	3553.00	2.75	0.08	5.31	7.59	16.82	29.80
Lead	2316.25	7.50	0.32	0.28	0.34	7.38	17.94

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	228.35	0.55	0.24	2.23	1.70	16.03	71.18
Cotton	112.32	0.67	0.59	3.21	5.55	8.12	48.75
Sugar	18.97	0.13	0.68	1.51	1.99	6.74	33.59
Wheat	791.50	3.75	0.48	2.76	0.54	7.47	23.38
Soybean	1357.00	11.75	0.86	1.65	10.64	6.68	25.04

Bangladesh drug maker Beximco launches world's first generic of Pfizer's COVID antiviral

Bangladesh drug maker Beximco Pharmaceuticals became the first company to launch a generic version of Pfizer's COVID-19 treatment Paxlovid. Paxlovid is a combination of nirmatrelvir and ritonavir tablets. Directorate General of Drug Administration (DGDA), Bangladesh granted EUA for the oral antiviral drug on 30 December 2021 to treat mild-to-moderate COVID-19 in adults and children of 12 years and above. Beximco Pharma will market this product under the brand name Bexovid. Pfizer's drug is protected by patents, but countries such as Bangladesh classified as least-developed countries (LDCs) by the United Nations can ignore such patents and make drugs more affordable in those markets. The TRIPS transition period for LDCs was extended till July 2034. Pfizer's novel antiviral pill showed almost 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent data from Pfizer suggests the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.

Gensol Engineering bags order worth Rs 22.50 crore in December

Solar energy solution provider Gensol Engineering has bagged orders to develop 10.7MWp grid-connected ground-mounted and rooftop solar power generating systems worth Rs 22.50 crore in December. According to the statement, Gensol Engineering Ltd has in December 2021, in the normal course of business, received purchase orders from its clients for the development of solar power projects aggregating to a capacity of around 10.7 MWp in Gujarat, Karnataka and Madhya Pradesh. The cumulative price of these projects is pegged at over Rs 22.50 crore, exclusive of taxes. While most of the projects are for captive use of the clients, one of the projects is for third-party sale in Gujarat. All these projects are slated for commissioning before March 31, 2022, and will entail a cumulative revenue of over Rs 22.50 crore, exclusive of taxes. As of December 29, 2021, the cumulative order book stands at more than Rs 131 crore following the closure of these projects.

Kalpataru Power bags orders worth Rs 1,560 crore

Kalpataru Power Transmission Ltd has bagged new orders worth Rs 1,560 crore. The orders include those from India, Africa, CIS and South America in the power transmission business. KPTL's international subsidiary has secured new power transmission projects in Europe.

NTPC arm NREL to float global tender to set up 3GW RE project worth Rs 15K cr by Feb

State-owned power giant NTPC arm NTPC Renewable Energy Ltd (NREL) will float a global engineering procurement and construction tender to set up a 3GW renewable energy project with a battery storage system worth around Rs 15,000 crore by February 2022. A request for proposal (RFP) is a business document that announces a project, describes, and solicits bids from qualified contractors to complete it. The development assumes significance given India's ambitious target of having 175GW of renewable energy by 2022, including 100GW of solar and 60 GW of wind energy. According to a Central Electricity Authority (CEA) report, as of November 30, 2022, India's renewable energy capacity excluding large hydro plants is 104GW, including 49GW solar and 40GW of wind energy. NREL, a 100 per cent subsidiary of NTPC Ltd, currently has a renewable project portfolio of 3,850 GW, of which, 970 MW projects are under construction and 2,880 MW projects have been won and are in different phases of implementation.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Tiaan Consumer Ltd	Corporate meeting effective of 31-12-2021
Uniply Decor Ltd	Corporate meeting effective of 31-12-2021
Bodhtree Consulting Ltd	Corporate meeting effective of 31-12-2021
Equipp Social Impact Technologies Ltd	Corporate meeting effective of 31-12-2021
Nova Iron & Steel Ltd	Corporate meeting effective of 31-12-2021
SS Organics	Corporate meeting effective of 31-12-2021
Vanta Bioscience Ltd	Corporate meeting effective of 31-12-2021
Ritesh Properties and Industries Ltd	Corporate meeting effective of 31-12-2021
Genomic Valley Biotech Ltd	Corporate meeting effective of 31-12-2021
Satin Creditcare Network Ltd	Corporate meeting effective of 31-12-2021
Billwin Industries Ltd	Corporate meeting effective of 31-12-2021
Neogen Chemicals Ltd	Corporate meeting effective of 31-12-2021
Laser Diamonds Ltd	Corporate meeting effective of 31-12-2021
Dhanada Corp Ltd	Corporate meeting effective of 31-12-2021

Domestic Events

- India Foreign Exchange Reserve for December 24, 2021.
- India Infrastructure Output for November 2021.

Global Events

- China NBS Manufacturing PMI for December 2021.
- China NBS Non Manufacturing PMI for December 2021.

Analyst Certification:

We /I, Jaydeb Dey and Deepankar Saha Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
